Skip to main content
. 2020 Apr 28;26(27):5965–5969. doi: 10.1002/chem.202001146

Figure 4.

Figure 4

Production of HSA/celastrol hybrid nanoparticles. (a) Celastrol is encapsulated within HSA nanoparticles by the microfluidic co‐flow device. This was achieved by adding celastrol to the EtOH phase and HSA as the protein phase. (b) TEM images of HSA/celastrol nanoparticles formed by using a 4:1 flow rate ratio (EtOH/protein). (c) The resulting hybrid nanoparticles have slightly broader size distributions. (d) The average diameter sizes were comparable to those of pure HSA nanoparticles. (e) Stability of HSA/celastrol nanoparticles in PBS and in 10 % human serum, followed over a 24 h time period. The release of celastrol from the nanoparticles to the outside environment was determined by HPLC. (f) Cell viability in RAW 264.7 murine macrophages with different concentrations of celastrol, either free in solution or incorporated into HSA nanoparticles.